Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMPH) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines across the United States, India, and Ireland. The company operates through three reportable segments: Affordable Medicines,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amneal Pharmaceuticals, Inc. does
In the company’s own words
Amneal Pharmaceuticals, Inc. (NASDAQ: AMPH) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines across the United States, India, and Ireland. The company operates through three reportable segments: Affordable Medicines, Specialty, and AvKARE.
The Affordable Medicines segment represents the company's largest business unit and includes over 280 product families covering extensive dosage forms and delivery systems, including immediate and extended-release oral solids, sterile injectables, nasal sprays, inhalation products, biosimilars, ophthalmics, and transdermal patches. This segment focuses on developing high-value products with complex formulations and substantial barriers to entry. The company has commercialized five biosimilars in the U.S. market, including ALYMSYS (referencing Avastin), Releuko (referencing Neupogen), Flynetra (referencing Neulasta), Boncresa (denosumab referencing Prolia), and Oziltus (denosumab referencing XGEVA). As of December 31, 2025, the segment had 61 products with pending applications and 43 products in various development stages, with 95 percent being non-oral solid products.
The Specialty segment develops and markets proprietary branded pharmaceutical products focused on central nervous system disorders, particularly Parkinson's disease, and endocrine disorders. Key products include CREXONT (carbidopa-levodopa extended release), RYTARY (carbidopa-levodopa), UNITHROID (levothyroxine sodium), and Brekiya (dihydroergotamine mesylate autoinjector).
The AvKARE segment provides pharmaceuticals primarily to U.S. federal government agencies, including the Department of Defense and Department of Veterans Affairs, and serves as a wholesale distributor to retail and institutional customers. The company maintains a network of manufacturing sites and research and development centers with broad dosage capabilities. For the year ended December 31, 2025, the four largest customers—Cencora, McKesson, Cardinal Health, and CVS Health—collectively accounted for approximately 71 percent of consolidated net revenue. The company serves approximately 1,300 customers overall.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Fiscal year end
- December
- CIK
- 1723128
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amneal Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Amneal Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Amneal Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Amneal Pharmaceuticals, Inc.’s debt, $177.99M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 6.88%, maturing 2032 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amneal Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amneal Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amneal Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”